Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stella Chemifa Of Japan To Commercialize Boron Isotope Cancer Treatment System

This article was originally published in PharmAsia News

Executive Summary

Osaka-based Stella Chemifa plans to commercialize its boron neutron capture treatment by 2011. BNCT uses neutron rays to radiate cancer tissues embedded with boron isotope chemical, and selectively kill cancer cells. By only destroying targeted cells and having no impact to other cells, BNCT can be used to treat malignant cancers such as brain tumors, mesothelioma, lung and liver cancer. Starting in 2009, clinical trials will be conducted jointly with Kyodo University's Research Reactor Institute. (Click here for more - Japanese language

You may also be interested in...



EU Health Ministers To Deliberate Over Commission’s Pharma Strategy

A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.

Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle

Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.

EU Approval Of COVID-19 Vaccines Possible In Weeks

The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel